Cochrane-GRADE Workshop

Similar documents
Washington, DC, November 9, 2009 Institute of Medicine

Copyright GRADE ING THE QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS NANCY SANTESSO, RD, PHD

Outcomes and GRADE Summary of Findings Tables: old and new

JBI GRADE Research School Workshop. Presented by JBI Adelaide GRADE Centre Staff

The Joanna Briggs Institute Reviewers Manual 2014

GRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2014

SOF: Summary of Findings tables. Negrar, 7 aprile 2018

GRADE, Summary of Findings and ConQual Workshop

Update on bronchiectasis guidelines. James Chalmers MD, PhD, FRCPE, FERS University of Dundee, UK

Does the evidence directly answer my question?

GRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2018

Objectives. Information proliferation. Guidelines: Evidence or Expert opinion or???? 21/01/2017. Evidence-based clinical decisions

Introduzione al metodo GRADE

Фармакоэкономика. теория и практика. Pharmacoeconomics. theory and practice

Early Rehabilitation in the ICU: Do We Still Need Chest Physiotherapy?

MINI SYMPOSIUM - EUMASS - UEMASS European Union of Medicine in Assurance and Social Security

EVIDENCE AND RECOMMENDATION GRADING IN GUIDELINES. A short history. Cluzeau Senior Advisor NICE International. G-I-N, Lisbon 2 November 2009

Vector control and policy: systematic reviews

CRITICAL APPRAISAL OF CLINICAL PRACTICE GUIDELINE (CPG)

Assessing quality of evidence The GRADE approach

U.S. Preventive Services Task Force Methods and Processes. Alex R. Kemper, MD, MPH, MS June 16, 2014

Determinants of quality: Factors that lower or increase the quality of evidence

Alcohol interventions in secondary and further education

'Summary of findings' tables in network meta-analysis (NMA)

Practice guidelines : overview of methodology with focus on GRADE

Water fluoridation: reviewing the evidence

Drug Class Review Newer Oral Anticoagulant Drugs

Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer Executive Summary

Overview and Comparisons of Risk of Bias and Strength of Evidence Assessment Tools: Opportunities and Challenges of Application in Developing DRIs

TITLE: Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis: A Review of Clinical Evidence, Benefits and Harms

VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT

Preventive Medicine 2009: Understanding the US Preventive Services Task Force Guidelines. *George F. Sawaya, MD

Less is more: Guidelines

Problem solving therapy

Guideline Development At WHO

Results. NeuRA Worldwide incidence April 2016

Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College

Results. NeuRA Hypnosis June 2016

New Guidance in AT10 Clive Kearon, MD, PhD,

Online Annexes (2-4)

Grading the Evidence Developing the Typhoid Statement. Manitoba 10 th Annual Travel Conference April 26, 2012

INTRODUCTION. Evidence standards for justifiable evidence claims, June 2016

What is sufficient evidence to inform combination HIV prevention programs. Stefan Baral

Traumatic brain injury

Results. NeuRA Treatments for internalised stigma December 2017

Standard Methods for Quality Assessment of Evidence

Workshop: Cochrane Rehabilitation 05th May Trusted evidence. Informed decisions. Better health.

Results. NeuRA Mindfulness and acceptance therapies August 2018

Results from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY

Evaluating the Strength of Clinical Recommendations in the Medical Literature: GRADE, SORT, and AGREE

NeuRA Sleep disturbance April 2016

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden

PGY1 Learning activities-ebcp Scripts

Guideline development in TB diagnostics. Karen R Steingart, MD, MPH McGill University, Montreal, July 2011

Canadian Cochrane Network & Centre. Copyright 05/12/2009 by Phil Hahn

Animal-assisted therapy

Duration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016

Daiichi Sankyo s Once-Daily Lixiana

Distraction techniques

Slide 1: Perioperative Management of Anticoagulation

Incorporating qualitative research into guideline development: the way forward

Evidence-based medicine and guidelines: development and implementation into practice

Obesity, renal failure, HIT: which anticoagulant to use?

Oral Anticoagulation Drug Class Prior Authorization Protocol

Technology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta245

Results. NeuRA Motor dysfunction April 2016

ASH Draft Recommendations for VTE Prevention in Surgical Hospitalized Patients DRAFT

11 questions to help you make sense of a case control study

Meta-Analysis. Zifei Liu. Biological and Agricultural Engineering

Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism

Results. NeuRA Forensic settings April 2016

PHO MetaQAT Guide. Critical appraisal in public health. PHO Meta-tool for quality appraisal

The evidence system of traditional Chinese medicine based on the Grades of Recommendations Assessment, Development and Evaluation framework

PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC

*Corresponding Author:

CASE IN... Anticoagulation: When to Start,When to Stop. The management of patients who require an. Meet Tracey. Anticoagulation

Controlled Trials. Spyros Kitsiou, PhD

Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines

Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H

Evidence-Based Medicine Journal Club. A Primer in Statistics, Study Design, and Epidemiology. August, 2013

CRITICAL APPRAISAL SKILLS PROGRAMME Making sense of evidence about clinical effectiveness. 11 questions to help you make sense of case control study

Physical Activity: Family-Based Interventions

CEU screening programme: Overview of common errors & good practice in Cochrane intervention reviews

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden

Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myo

INTRODUCTION WHAT ARE PROFESSIONAL SOCIETIES AND OTHER ORGANIZATIONS DOING NOW?

Treatment decisions involve a trade-off between benefits

Society of Trauma Nurses TraumaCon 03/22/2018

Consequences of stroke and AF

Approaches to Integrating Evidence From Animal and Human Studies in Chemical Assessments

Results. NeuRA Family relationships May 2017

Cochrane Update Assessing evidence in public health: the added value of GRADE

Management of Suspected Opioid Overdose With Naloxone by EMS Personnel

Bristol-Myers Squibb/Pfizer Alliance Independent Medical Education

Cover Page. The handle holds various files of this Leiden University dissertation.

Authors face many challenges when summarising results in reviews.

Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life

Primary Care practice clinics within the Edmonton Southside Primary Care Network.

MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC

Interpreting Levels of Evidence and Grades of Health Care Recommendations

Transcription:

Cochrane-GRADE Workshop Modena, June 2017 Holger Schünemann, Elena Parmelli, Sara Balduzzi Jane Noyes, Heather Munthe-Kaas, Claire Glenton

Background / history of GRADE and GRADE CERQual

Deep vein thrombosis and pulmonary embolism (VTE) The risk of VTE is elevated in cancer (4 5% annually) Require hospital admission and interventions at end of life Associated with impairments in function, pain and increased costs

A clinically sensible question Population: the impact of In patients with (lung) cancer, what is Intervention: (comparison) Outcomes: heparin compared with no heparin on the risk for venous thromboembolism, death, bleeding, burden? PICO

A systematic review of RCTs: heparins in cancer patients Akl & Schünemann, New Engl J Med, 2012

Do you have confidence in these estimates of effects? About here? 100% confident About here? About here? About here? 0% confident Akl & Schünemann, New Engl J Med, 2012

Certainty of the evidence? How confident in the research? GRADE Are the research studies well done? Are the results consistent across studies when they should be? How directly do the results relate to our question? Is this effect size precise or likely due to random error? Are these all of the studies that have been conducted? Plus factors that increase certainty e.g. large intervention effects

Magnitude of effect/associ ation Likelihood of and certainty in the evidence or effect Certainty of evidence Confidence in association/effect I figure there s a 40% chance of showers and a 10% chance we know what we are talking about.

Systematic review process 1. define the question 2. plan eligibility criteria 3. plan methods 4. search for studies 5. apply eligibility criteria 6. collect data 7. assess studies for risk of bias 8. analyze and present results 9. interpret results and draw conclusions 10.improve and update review Historically not a lot of guidance for this

Cochrane reviews. interpret results and draw conclusions? GRADE criteria (MECIR standards: mandatory)

Clinical Practice guidelines & the origin of evidence appraisal systems Canadian Task Force on the Periodic Health Examination, CMAJ, 1979

Chest 1986

Chest 1995

Evidence of Execution Effectiveness - Good or Fair Strong Good Design Suitability Greatest, Moderate, or Least Greatest Level of Certainty USPSTF Good High Description Number of Studies Consistent Effect Sized Expert Opinion At Least 2 Yes Sufficient Not Used Greatest or At Least 5 Yes Sufficient Not Used The available evidence usually includes consistent results from well-designed, wellmoderate conducted studies in representative primary care populations. These studies assess the Greatest At Least 5 Yes Sufficient Not Used effects of the preventive service on health outcomes. This conclusion is therefore Good or Fair unlikely to be strongly affected by the results of future studies. Meet Design, Execution, Number, and Consistency Criteria for Large Not Used Moderate The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the estimate is constrained by such factors as: Sufficient But Not Strong Evidence The number, size, or quality of individual studies. Sufficient Antithrombotic therapy guidelines. Chest 1989 Good Greatest 1 Not Sufficient Not Used Inconsistency of findings across individual studies. http://www.plasticsurgery.org/ Applicable Limited generalizability of findings to routine primary care practice. Good or Greatest or At Least 3 Yes Sufficient Not Used Lack of coherence in the chain of evidence. Fair Moderate As more information becomes available, the magnitude or direction of the observed effect could change, and this change may be large enough to alter the conclusion. Good or Greatest, At Least 5 Yes Sufficient Not Used Low Fair The available evidence is insufficient to assess effects on health outcomes. Evidence is Moderate, or Least insufficient because of: The limited number or size of studies. Expert Opinion Varies Varies Varies Varies Sufficient Supports a Important flaws in study design or methods. Recommendation Inconsistency of findings across individual studies. Insufficient A.Insufficient Designs or B. Too Few C. D. Small E. Not Used Gaps in the chain of evidence. Execution Studies Inconsistent Findings not generalizable to routine primary care practice. Lack of information on important health outcomes. More information may allow estimation of effects on health outcomes.

Which hierarchy? Recommendation for use of oral anticoagulation in patients with atrial fibrillation and rheumatic mitral valve disease Evidence Recommendation B Class I A 1 IV C Organization ØAHA ØACCP ØSIGN

Simple hierarchies are (too) simplistic STUDY DESIGN n n n Randomized Controlled Trials Cohort Studies and Case Control Studies Case Reports and Case Series, Non-systematic observations Expert Opinion BIAS Expert Opinion Schünemann & Bone, 2003

BMJ 2003 BMJ, 2003

Relative risk reduction:.> 99.9 % (1/100,000) U.S. Parachute Association reported 821 injuries and 18 deaths out of 2.2 million jumps in 2007 BMJ 2003

Aim: to develop a common, transparent and sensible system for grading the quality of evidence and the strength of recommendations

Meeting minutes London 2002 G RADE 2002

Developed a unifying, transparent and sensible system for grading the certainty of evidence and developing recommendations/making decisions NICE, WHO, CDC, AHRQ, professional societies, academic institutions For systematic reviews, HTA and guidelines International contributors (>500) with diversity in background 2008 BMJ series; 2011 JCE series over 30,000 cites Various other publications (incl. GRADE Handbook) IT applications CMAJ 2003, BMJ 2004, BMC 2004, BMC 2005, AJRCCM 2006, Chest 2006, BMJ 2008, JCE 2011-2016

GRADE Centers GRADE Networks McMaster University GRADE Center, Canada Lanzhou University GRADE Center, China Barcelona GRADE Center, Spain Freiburg University GRADE Center, Germany American University of Beirut GRADE Center, Lebanon Lazio Region-ASL Rome GRADE Center, Italy Javeriana Bogota GRADE Center, Colombia JBI Adelaide GRADE Center, Australia U.S. GRADE Network, United States Dutch GRADE Network, Netherlands UK GRADE Network, United Kingdom

Over 100 organizations adopted or use GRADE Open membership free: www.gradeworkingroup.org

Certainty of the evidence? How confident in the research? GRADE Are the research studies well done? Are the results consistent across studies when they should be? How directly do the results relate to our question? Is this effect size precise or likely due to random error? Are these all of the studies that have been conducted? Plus factors that increase certainty e.g. large intervention effects

Determinants of certainty of evidence RCTs ÅÅÅÅ high observational studies ÅÅ low 5 factors that can lower quality 1. limitations in detailed study design and execution (risk of bias criteria) 2. Inconsistency (or heterogeneity) 3. Indirectness (PICO and applicability) 4. Imprecision 5. Publication bias 3 factors can increase quality 1. large magnitude of effect 2. opposing plausible residual bias or confounding 3. dose-response gradient

Assessing Certainty in Evidence by Outcome For each outcome based on a systematic review and across outcomes (lowest certainty across the outcomes critical for decision making) 1. Establish initial level of certainty 2. Consider lowering or raising level of certainty 3. Final level of certainty rating Study design Initial certainty of evidence Reasons for considering lowering or raising certainty Certainty of the evidence across those considerations ê Lower if é Higher if* Randomized trialsè High certainty Risk of Bias Inconsistency Large effect Dose response High Observational studiesè Low certainty Indirectness Imprecision Publication bias All plausible confounding & bias would reduce a demonstrated effect or would suggest a spurious effect if no effect was observed Moderate Low Very low *upgrading criteria are usually applicable to observational studies only.

Lowering certainty in RCTs For each outcome based on a systematic review and across outcomes (lowest certainty across the outcomes critical for decision making) 1. Establish initial level of certainty 2. Consider lowering or raising level of certainty 3. Final level of certainty rating Study design Initial certainty of evidence Reasons for considering lowering or raising certainty Certainty of the evidence across those considerations ê Lower if é Higher if* Randomized trialsè High certainty Risk of Bias Inconsistency Large effect Dose response High Observational studiesè Low certainty Indirectness Imprecision Publication bias All plausible confounding & bias would reduce a demonstrated effect or would suggest a spurious effect if no effect was observed Moderate Low Very low *upgrading criteria are usually applicable to observational studies only.

Altering certainty of non-randomized studies For each outcome based on a systematic review and across outcomes (lowest certainty across the outcomes critical for decision making) 1. Establish initial level of certainty 2. Consider lowering or raising level of certainty 3. Final level of certainty rating Study design Initial certainty of the evidence Reasons for considering lowering or raising certainty Certainty of the evidence across those considerations ê Lower if é Higher if* Randomized trialsè High confidence Risk of Bias Inconsistency Large effect Dose response High Observational studiesè Low confidence Indirectness Imprecision Publication bias All plausible confounding & bias would reduce a demonstrated effect or would suggest a spurious effect if no effect was observed Moderate Low Very low *upgrading criteria are usually applicable to observational studies only.

Certainty of evidence Assess evidence transparently across all domains Confidence in an estimate? Starts with single research studies Ends with a body of evidence by health outcome high, moderate, low, very low certainty Recommendations/Decisions Involves making judgments and decisions transparent Evidence to Decision (EtD) frameworks Comprehensive list of criteria that influence a decision or recommendation Clearly developed & formulated action message Strong or conditional recommendations for or against an option 2 principles

P I/E C O Outcome Outcome Outcome Outcome Evidence synthesis (systematic review/hta) Critical Critical Important Not Create evidence profile/sof Table with GRADEpro Summary of findings & estimate of effect for each outcome Randomization raises Rate quality of initial quality evidence for RCTs: high each outcome Observational: low High Moderate Low Very low Grade down Grade up 1. Risk of bias 2. Inconsistency 3. Indirectness 4. Imprecision 5. Publication bias 1. Large effect 2. Dose response 3. Opposing bias & Confounders Recommendation/Decision Grade recommendations (Evidence to Recommendation) For or against (direction) Strong or conditional/weak (strength) By considering balance of consequences (evidence to recommendations): q Quality of evidence q Balance benefits/harms q Values and preferences (equity) q Resource use (cost, feasibility) q Acceptability EtD framwork Guideline/Decision Grade overall quality of evidence across outcomes based on lowest quality of critical outcomes Formulate Recommendations ( Å ) The panel recommends that.should... The panel suggests that.should... The panel suggests to not... The panel recommends to not... Transparency, clear, actionable

A clinically sensible question Population: the impact of In patients with (lung) cancer, what is Intervention: (comparison) Outcomes: heparin compared with no heparin on the risk for venous thromboembolism, death, bleeding, burden? PICO

Do you have confidence in these estimates of effects? About here? 100% confident About here? About here? About here? 0% confident Akl & Schünemann, New Engl J Med, 2012

Determinants of quality/certainty of a body of evidence RCTs ÅÅÅÅ observational studies (NRS) ÅÅ 5 factors that can lower quality 1. limitations in detailed study design and execution (risk of bias criteria) 2. Inconsistency (or heterogeneity) 3. Indirectness (PICO and applicability) 4. Imprecision 5. Publication bias 3 factors can increase quality 1. large magnitude of effect 2. opposing plausible residual bias or confounding 3. dose-response gradient

R isk of bias within & across